Read by QxMD icon Read

estrogen aggression

Touria Derkaoui, Joaira Bakkach, Mohamed Mansouri, Ali Loudiyi, Mohamed Fihri, Fatima Zahra Alaoui, Amina Barakat, Bouchra El Yemlahi, Hassan Bihri, Naima Ghailani Nourouti, Mohcine Bennani Mechita
BACKGROUND: Triple Negative Breast Cancer (TNBC) is defined by a lack of estrogen and progesterone receptor gene expression and by the absence of overexpression on HER2. It is associated to a poor prognosis. We propose to analyze the clinicopathologic and prognostic characteristics of this breast cancer subtype in a Mediterranean population originated or resident in the North of Morocco. METHODS: We conducted a retrospective study of 279 patients diagnosed with breast cancer between January 2010 and January 2015...
October 22, 2016: BMC Women's Health
Hui Yao, Guangchun He, Shichao Yan, Chao Chen, Liujiang Song, Thomas J Rosol, Xiyun Deng
Triple-negative breast cancer (TNBC), which accounts for 15-20% of all breast cancers, does not express estrogen receptor (ER) or progesterone receptor (PR) and lacks human epidermal growth factor receptor 2 (HER2) overexpression or amplification. These tumors have a more aggressive phenotype and a poorer prognosis due to the high propensity for metastatic progression and absence of specific targeted treatments. Patients with TNBC do not benefit from hormonal or trastuzumab-based targeted therapies because of the loss of target receptors...
September 27, 2016: Oncotarget
Edlira Pajenga, Tefta Rexha, Silva Çeliku, Ana Ugrinska, Gazmend Bejtja
AIM: This retrospective study was designed to analyze expression patterns of estrogen receptor (ER), progesterone receptor (PR) and HER2/neu in Albanian patients with breast carcinoma to identify their relationships with tumor size, histological grade (HG), lymph node metastasis and relapse. METHODS: Patients with either biopsy or metastatic relapse were identified. Demographics, tumor characteristics, ER, PR, and HER2/neu status were retrospectively obtained from the medical records of patients treated with breast cancer during 2006-2011...
September 2016: Central European Journal of Public Health
Kimberly A Bertrand, Traci N Bethea, Lucile L Adams-Campbell, Lynn Rosenberg, Julie R Palmer
BACKGROUND: Given the disproportionately high incidence of early-onset breast cancer and aggressive subtypes such as estrogen receptor (ER) negative tumors in African American (AA) women, elucidation of risk factors for early-onset of specific subtypes of breast cancer is needed. METHODS: We evaluated associations of reproductive, anthropometric, and other factors with incidence of invasive breast cancer by age at onset (<45, {greater than or equal to}45) in 57,708 AA women in the prospective Black Women's Health Study...
October 18, 2016: Cancer Epidemiology, Biomarkers & Prevention
Maike Zimmermann, Aruni P S Arachchige-Don, Michaela S Donaldson, Tommaso Patriarchi, Mary C Horne
Definition of cell cycle control proteins that modify tumor cell resistance to estrogen (E2) signaling antagonists could inform clinical choice for estrogen receptor positive (ER+) breast cancer (BC) therapy. Cyclin G2 (CycG2) is upregulated during cell cycle arrest responses to cellular stresses and growth inhibitory signals and its gene, CCNG2, is directly repressed by E2-bound ER complexes. Our previous studies showed that blockade of HER2, PI3K and mTOR signaling upregulates CycG2 expression in HER2+ BC cells, and that CycG2 overexpression induces cell cycle arrest...
October 18, 2016: Cell Cycle
Charli S Davies, Kendra N Smyth, Lydia K Greene, Debbie A Walsh, Jessica Mitchell, Tim Clutton-Brock, Christine M Drea
In vertebrates, reproductive endocrine concentrations are strongly differentiated by sex, with androgen biases typifying males and estrogen biases typifying females. These sex differences can be reduced in female-dominant species; however, even the most masculinised of females have less testosterone (T) than do conspecific males. To test if aggressively dominant, female meerkats (Suricata suricatta) may be hormonally masculinised, we measured serum androstenedione (A4), T and estradiol (E2) in both sexes and social classes, during both 'baseline' and reproductive events...
October 18, 2016: Scientific Reports
Xiangyan Ruan, Ying Zhang, Alfred O Mueck, Marina Willibald, Harald Seeger, Tanja Fehm, Sara Brucker, Hans Neubauer
OBJECTIVE: Expression of progesterone receptor membrane component 1 (PGRMC1) has been shown to be higher in breast cancer than normal tissue. We have previously shown that certain progestogens strongly stimulate proliferation of breast cancer cells overexpressing PGRMC1, and therefore hypothesize that PGRMC1 may play a critical role in breast cancer progression. Because little information is available if expression of PGRMC1 is also associated with worse prognosis for breast cancer patients, in this study we investigated the clinicopathologic significance of PGRMC1 expression in breast cancer tissue...
October 3, 2016: Menopause: the Journal of the North American Menopause Society
Wenyan Wang, Xin Wang, Jiaqi Liu, Jidong Gao, Jie Wang, Xiang Wang, Dongbing Zhao
BACKGROUND: Breast cancer has aggressive clinical and pathological features in younger women and is characterized by poorer prognosis than in older women. However, data on women <25 years are limited. OBJECTIVE: The aim of the present study was to evaluate the different pathological characteristics and prognostic factors in Chinese women with breast cancer <25 years at the time of diagnosis. METHODS: This retrospective study included 94 patients (aged <25) of Chinese Han population with operable breast cancer at the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences between January 1, 2000 and September 30, 2015...
September 3, 2016: Pathology, Research and Practice
Jeff Johnson, Michael Choi, Farnaz Dadmanesh, Bingchen Han, Ying Qu, Yi Yu-Rice, Xiao Zhang, Sanjay Bagaria, Clive Taylor, Armando E Giuliano, Farin Amersi, Xiaojiang Cui
Breast cancers arising in the setting of the hereditary breast cancer genes BRCA1 and BRCA2 are most commonly classified as basal-like breast cancer (BLBC) or luminal breast cancer, respectively. BLBC is an aggressive subtype of breast cancer associated with liver and lung metastases and poorer prognosis than other subtypes and for which chemotherapy is the only systemic therapy. Multiple immunohistochemical markers are used to identify the basal-like subtype, including the absence of estrogen receptor alpha, progesterone receptor, and human epidermal growth factor receptor 2...
September 30, 2016: Oncotarget
Jar-Yi Ho, Ren-Jun Hsu, Jui-Ming Liu, Szu-Chi Chen, Guo-Shiou Liao, Hong-Wei Gao, Cheng-Ping Yu
Aberrant activation of the Ras/ERK pathway mediates breast cancer initiation and aggressiveness. Therefore, it is important to identify miRNAs that modulate the Ras/ERK pathway during breast carcinogenesis and progression. The Ras GTPase superfamily member RERG (Ras-related and estrogen-regulated growth inhibitor) acts as a tumor suppressor to reduce breast cancer cell proliferation and tumor formation and has been suggested to have a regulatory role in the Ras/ERK pathway. In this study, we found that RERG exerted its tumor suppressor role by attenuating the activation of Ras/ERK signaling effectors...
September 29, 2016: Oncotarget
Renata Duchnowska, Michał Jarząb, Jadwiga Żebracka-Gala, Rafał Matkowski, Anna Kowalczyk, Barbara Radecka, Małgorzata Kowalska, Aleksandra Pfeifer, Małgorzata Foszczyńska-Kłoda, Antonino Musolino, Bogumiła Czartoryska-Arłukowicz, Maria Litwiniuk, Anna Surus-Hyla, Sylwia Szabłowska-Siwik, Bożenna Karczmarek-Borowska, Sylwia Dębska-Szmich, Beata Głodek-Sutek, Katarzyna Sosińska-Mielcarek, Ewa Chmielowska, Ewa Kalinka-Warzocha, Wojciech P Olszewski, Janusz Patera, Anton Żawrocki, Agnieszka Pliszka, Tomasz Tyszkiewicz, Dagmara Rusinek, Małgorzata Oczko-Wojciechowska, Jacek Jassem, Wojciech Biernat
BACKGROUND: Triple-negative breast cancer (TNBC) lacks expression of steroid hormone receptors (estrogen receptor α and progesterone) and epidermal growth factor receptor type 2. This phenotype shows high metastatic potential, with particular predilection to lungs and brain. Determination of TNBC transcriptomic profiles associated with high risk of brain metastasis (BM) might identify patients requiring alternative, more aggressive, or specific preventive and therapeutic approaches. PATIENTS AND METHODS: Using a cDNA-mediated annealing, selection, extension, and ligation assay, we investigated expression of 29,369 gene transcripts in primary TNBC tumor samples from 119 patients-71 in discovery cohort A and 48 in independent cohort B-that included best discriminating genes...
September 8, 2016: Clinical Breast Cancer
Lahong Zhang, Zhaojun Chen, Dan Xue, Qi Zhang, Xiyong Liu, Frank Luh, Liquan Hong, Hang Zhang, Feng Pan, Yuhua Liu, Peiguo Chu, Shu Zheng, Guoqiang Lou, Yun Yen
Mitochondrial serine hydroxylmethyltransferase 2 (SHMT2) is a key enzyme in the serine/glycine synthesis pathway. SHMT2 has been implicated as a critical component for tumor cell survival. The aim of the present study was to evaluate the prognostic value and efficiency of SHMT2 as a biomarker in patients with breast cancer. Individual and pooled survival analyses were performed on five independent breast cancer microarray datasets. Gene signatures enriched by SHMT2 were also analyzed in these datasets. SHMT2 protein expression was detected using immunohistochemistry (IHC) assay in 128 breast cancer cases...
September 20, 2016: Oncology Reports
Valeria Hansberg-Pastor, Aliesha González-Arenas, Ignacio Camacho-Arroyo
Many progesterone (P4) actions are mediated by its intracellular receptor (PR), which has two isoforms (PR-A and PR-B) differentially transcribed from separate promoters of a single gene. In glioblastomas, the most frequent and aggressive brain tumors, PR-B is the predominant isoform. In an in silico analysis we showed putative CCAAT/Enhancer Binding Protein (C/EBP) binding sites at PR-B promoter. We evaluated the role of C/EBPβ in PR-B expression regulation in glioblastoma cell lines, which expressed different ratios of PR and C/EBPβ isoforms (LAP1, LAP2, and LIP)...
September 20, 2016: Molecular and Cellular Endocrinology
Katsuya Nakai, Mien-Chie Hung, Hirohito Yamaguchi
Triple-negative breast cancer (TNBC), which lacks estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), accounts for about 15-20% of breast cancers and is the most aggressive breast cancer subtype. There are currently no effective therapies against metastatic TNBC. Compared with other breast cancer subtypes, EGFR is frequently overexpressed in TNBC and a potential therapeutic target for this disease. There are two types of EGFR inhibitors, small molecular tyrosine kinase inhibitor (TKI) and monoclonal antibody (mAb), for the treatment of cancers, such as non-small cell lung cancer and colorectal cancer...
2016: American Journal of Cancer Research
Anna Badowska-Kozakiewicz, Maria Sobol, Janusz Patera
BACKGROUND: Expression of hypoxia-inducible factor 1α (HIF-1α) reflects the degree of cell hypoxia and its increased expression was found in most neoplasms, their metastasis as well as in some precancerous lesions. OBJECTIVES: The study aimed to investigate the expression HIF-1α in invasive breast cancer with metastasis to lymph nodes in correlation with steroid receptors (ER-estrogen receptor, PR-progesterone receptor), HER2 (human epidermal growth factor receptor 2) and EPO-R (erythropoietin receptor)...
July 2016: Advances in Clinical and Experimental Medicine: Official Organ Wroclaw Medical University
Esther H Lips, Rashmie Debipersad, Caroline E Scheerman, Lennart Mulder, Gabe S Sonke, Lizet E van der Kolk, Jelle Wesseling, Frans B L Hogervorst, Petra M Nederlof
Purpose As estrogen receptor (ER)-positive breast cancer in BRCA1 mutation carriers arises at an older age with less aggressive tumor characteristics than ER negative BRCA1 mutated breast cancer, it has been suggested that these tumors are 'sporadic' and not BRCA1-driven. With the introduction of targeted treatments specific for tumors with a non-functioning BRCA1 or BRCA2 gene, the question whether the BRCA genes are impaired in the tumor, is highly relevant. Therefore, we performed genomic profiling of BRCA1-mutated ER+ tumors...
September 12, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Catherine T Clinard, Abigail K Barnes, Samuel G Adler, Matthew A Cooper
Winning aggressive disputes is one of several experiences that can alter responses to future stressful events. We have previously tested dominant and subordinate male Syrian hamsters in a conditioned defeat model and found that dominant individuals show less change in behavior following social defeat stress compared to subordinates and controls, indicating a reduced conditioned defeat response. Resistance to the effects of social defeat in dominants is experience-dependent and requires the maintenance of dominance relationships for 14days...
September 9, 2016: Hormones and Behavior
Chansub Park, Kyeongmee Park, Jiyoung Kim, Youngjoo Sin, Inseok Park, Hyunjin Cho, Keunho Yang, Byung Noe Bae, Ki Whan Kim, Sookyung Ahn, Geumhee Gwak
BACKGROUND: The luminal subtype of breast cancer is sensitive to anti-estrogen therapy and shows a better prognosis than that of human epidermal growth factor receptor2 (HER2)-enriched or triple-negative breast cancer. However, the luminal type of breast cancer is heterogeneous and can have aggressive clinical features. We investigated the clinical implications of single hormone receptor negativity in a luminal B HER2-negative group. METHODS: We collected luminal B HER2-negative breast cancer data that were estrogen receptor (ER) and/or progesterone receptor (PR) positive, Ki 67 high (>14 %), and HER2 negative and divided them into the ER- and PR-positive group and the ER- or PR-negative group...
2016: World Journal of Surgical Oncology
J M Guillén-Muñoz, C A Meza-Herrera, Z Santos-Jimenez, R Rivas-Muñoz, J R Luna-Orozco, M Mellado, F G Véliz-Deras
Two trials were conducted to evaluate the effect of diverse socio-sexual cues upon male sexual behavior and the reproductive performance of anestrous does (AD). Trials were conducted in northern Mexico (26°N) during the natural anestrous season (Feb-Mar) with crossbred dairy bucks. In Experiment 1, sexually inactive bucks (SIB, n=12) were randomly allotted to three groups, four males/group: a) DEE 9novelty stimulation) - daily exchange of estrogenized females (EF) 12&12h, b) NEE (no novelty stimulation) - no-exchange of EF, 24h, or c) CON (saline-treated_ -daily exchange of AF 12&12h...
October 2016: Animal Reproduction Science
Keunhee Oh, Ok-Young Lee, Yeonju Park, Myung Won Seo, Dong-Sup Lee
BACKGROUND: We previously reported that IL-6 and transglutaminase 2 (TG2) were expressed in more aggressive basal-like breast cancer cells, and TG2 and IL-6 expression gave these cells stem-cell-like phenotypes, increased invasive ability, and increased metastatic potential. In the present study, the underlying mechanism by which IL-6 production is induced in luminal-type breast cancer cells was evaluated, and TG2 overexpression, IL-1β stimulation, and IL-6 expression were found to give cancerous cells a hormone-independent phenotype...
2016: BMC Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"